Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria

• •Participants should have successfully completed treatment in the M16-046 study, without meeting any permanent discontinuation criteria.
• •Participant is judged to be in general good health (other than AD) as determined by the Principal Investigator and remains eligible as per the criteria for the study M16-046 to continue treatment in the long term extension study.